HRMY
Harmony Biosciences Holdings, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 21.01K | $831,838 | n/a | n/a |
| Q2 2026 | 113 | +5 | 37.66M | $1.37B | +12 | −6 |
| Q1 2026 | 110 | -3 | 39.20M | $1.10B | +5 | −9 |
| Q4 2025 | 114 | +1 | 39.01M | $1.46B | +2 | n/a |
| Q3 2025 | 20 | +1 | 24.69M | $680.58M | +2 | −2 |
| Q2 2025 | 17 | -1 | 23.07M | $729.13M | +1 | −2 |
| Q1 2025 | 15 | +1 | 6.74M | $223.55M | +1 | n/a |
| Q4 2024 | 14 | -1 | 7.61M | $261.77M | n/a | −1 |
| Q3 2024 | 14 | +1 | 3.56M | $142.57M | +1 | n/a |
| Q2 2024 | 13 | n/a | 3.50M | $105.70M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wealth Enhancement Advisory… | 21.01K | +12.4% | $831,838 | 0.0% | ▲ Add | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 306 holders, 54.70M shares, $1.38B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 35.85K sh · $1.54M
Officer · 800 sh · $34,400
Officer · 1.80K sh · $77,426
Officer · 22.95K sh · $989,350
Officer · 1.00K sh · $42,795
Officer · 4.50K sh · $190,114
Officer · 5.50K sh · $230,911
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology